[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100503310":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":23,"locations":29,"responsibleParty":48,"collaborators":10,"id":50,"slug":10,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":10,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Anhui Provincial Hospital","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental",null,"Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs",[13],"Dietary Supplement: Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs",{"label":15,"type":10,"description":16,"interventionNames":17},"Comparator","Whole-course nutrition Combined With Chemoradiotherapy±ICIs",[13],[19],{"type":20,"name":11,"description":21,"armGroupLabels":22,"otherNames":10},"DIETARY_SUPPLEMENT","The Experimental group received a combination of omega-3 fatty acids, and glutamine, whereas the control group received standard formula.",[15,9],[24],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"dong qian, M.D.","CONTACT","+86-19156007756","qiankeyu1983@163.com",[30],{"facility":31,"status":32,"city":33,"state":10,"zip":10,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Anhui provincial hospital","RECRUITING","Hefei","China","CN",{"type":37,"coordinates":38},"Point",[39,40],117.28083,31.86389,{"lat":40,"lon":39},[43,44],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},{"name":45,"role":26,"phone":46,"phoneExt":10,"email":47},"Yuan He, M.D.","+86-18926243766","heyuan3766@126.com",{"type":49,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100503310",false,"NCT05833594","Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma","Anhui Provincial Hospita","Inclusion Criteria:\n\n* 18-85 years old;\n* Eastern Cooperative Oncology Group (ECOG) 0-2;\n* Esophageal squamous cell carcinoma;\n* cT2-4aN0-3M0 (AJCC 8th) confirmed by radiological examination;\n* initial unresectable at initial diagnosis confirmed by thoracic surgeons;\n* Treatment naive;\n* No contraindications for adjuvant chemoradiotherapy;\n* Signature of inform consent.\n\nExclusion Criteria:\n\n* younger than 18 years old or older than 85 years old;\n* ECOG\\>2;\n* Esophageal adenocarcinoma, small-cell cancer and other pathological types;\n* cT1anyNM0, cT4banyNM0, c anyTanyNM0 confirmed by radiological examination;\n* Resectable at initial diagnosis confirmed by thoracic surgeons;\n* Previous treatment of chemotherapy, radiotherapy, and other treatment;\n* Contraindications for chemoradiotherapy;\n* No signature of inform consent.","ALL","18 Years","85 Years",{"count":60,"type":61},70,"ESTIMATED","OBSERVATIONAL","Chemoradiotherapy has been a standard modality for inoperable locally advance esophageal carcinoma. The goal of this randomized control study is to compare the feasibility, and survival benefits of whole-course immunonutrition combined with chemoradiotherapy±ICIs for local advanced patients with inoperable esophageal squamous cell carcinoma. The main questions it aims to answer are: • If the feasibility and safety of whole-course immunonutrition combined with chemoradiotherapy±ICIs is better. • If the survival benefits (1, 2 and 3-years progression free survival) of whole-course immunonutrition combined with chemoradiotherapy±ICIs is longer. The Experimental group will receive a combination immunonutrition of omega-3 fatty acids, and glutamine, whereas the control group will receive standard formula.",[65,66,67,68],"Esophageal Squamous Cell Carcinoma","Chemoradiotherapy","Immunonutrition","Inoperable","2023-12-20",{"date":71,"type":72},"2023-12-26","ACTUAL",{"date":74,"type":72},"2023-07-01",{"date":76,"type":61},"2026-12-01",{"name":5,"class":6},1]